Estrella Immunopharma has dosed the first patient in the dose-expansion segment of its STARLIGHT-1 Phase I/II trial underway, assessing EB103 for relapsed or refractory (r/r) B-cell non-Hodgkin’s lymphoma (NHL).
EB103 is a Cluster of Differentiation 19 (CD19)-redirected ARTEMIS T-cell therapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The move to the dose-expansion cohort follows earlier findings from the dose-escalation stage.
In that stage, patients who achieved complete response at the Phase I six-month evaluation, and who did not have central nervous system involvement, maintained their complete response status.
The multi-centre, open-label trial is intended to further investigate the safety and efficacy of EB103 at the recommended Phase II dose in participants aged 18 years and older with r/r B-cell NHL.
Information gathered from this expansion cohort will inform the strategy for any pivotal trial involving EB103. The trial is currently recruiting at Baylor Scott & White Research Institute and UC Davis Comprehensive Cancer Center.
EB103 utilises ARTEMIS technology, licensed from Estrella’s parent company Eureka Therapeutics.
Unlike conventional CAR-T cells, ARTEMIS T-cells such as EB103 are designed to activate and regulate upon target engagement with cancer targets along mechanisms similar to endogenous T-cell receptors, aiming to bind and destroy CD19-positive cancer cells.
Estrella Immunopharma is also developing EB104, targeting both CD19 and CD22 in B-cell malignancies using the same technology.
Both therapeutic candidates are part of the company’s research in T-cell therapies for cancer and autoimmune conditions.
Estrella Immunopharma CEO Cheng Liu said: “This marks an important milestone for Estrella and STARLIGHT-1. The sustained complete responses observed to date reinforce EB103’s potential to deliver best-in-class outcomes for patients with R/R B-cell NHL. We remain deeply committed to advancing EB103.”
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
